In another 48-week phase 2 study including obese patients, weekly triple hormone (GLP-1/GIP/GCG) RA retatrutide (RETA: LY3437943) was investigated for obesity treatment in 338 obese patients, and 98 of those also suffered from MASLD [111]. The gene discussed is GIP; the disease is obesity disorder.